Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(16), P. 4919 - 4919
Published: Aug. 20, 2024
Vitiligo
is
a
persistent
autoimmune
disease
characterized
by
progressive
depigmentation
of
the
skin
caused
selective
destruction
melanocytes.
Although
its
etiopathogenesis
remains
unclear,
multiple
factors
are
involved
in
development
this
disease,
from
genetic
and
metabolic
to
cellular
oxidative
stress,
melanocyte
adhesion
defects,
innate
adaptive
immunity.
This
review
presents
comprehensive
summary
existing
knowledge
on
role
different
mechanisms,
including
cytokines
chemokines
interactions,
pathogenesis
vitiligo.
there
no
definitive
cure
for
vitiligo,
notable
progress
has
been
made,
several
treatments
have
shown
favorable
results.
A
thorough
understanding
basis
uncovers
promising
drug
targets
future
research,
providing
clinical
researchers
with
valuable
insights
developing
improved
treatment
options.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(18), P. 10201 - 10201
Published: Sept. 23, 2024
While
vitiligo
is
primarily
caused
by
melanocyte
deficiency
or
dysfunction,
recent
studies
have
revealed
a
notable
prevalence
of
metabolic
syndrome
(MetS)
among
patients
with
vitiligo.
This
suggests
shared
pathogenic
features
between
the
two
conditions.
Individuals
often
exhibit
variations
in
triglyceride
levels,
cholesterol,
and
blood
pressure,
which
are
also
affected
MetS.
Given
similarities
their
underlying
mechanisms,
genetic
factors,
pro-inflammatory
signalling
pathways,
increased
oxidative
stress,
this
study
aims
to
highlight
common
traits
systemic
disorders.
Serum
analyses
confirmed
low-density
lipoprotein
(LDL)
levels
vitiligo,
compared
physiological
values.
In
addition,
we
reported
significant
decreases
folate
vitamin
D
(Vit
D)
levels.
Oxidative
stress
one
causes
development
syndromes
related
advancement
skin
diseases.
found
high
inflammatory
cytokines,
such
as
interleukin-6
(IL-6)
chemokine
10
(CXCL10),
markers
inflammation
disease
progression.
The
accumulation
insulin
growth
factor
binding
proteins
5
(IGFBP5)
advanced
glycation
end
products
(AGEs)
entailed
atherosclerosis
diabetes
onset,
respectively,
were
disclosed
blood-associated
activity
antioxidant
enzymes
catalase
(Cat)
superoxide
dismutase
(SOD)
was
impaired.
Moreover,
plasma
fatty
acid
(FAs)
profile
analysis
showed
an
alteration
composition
specific
estimated
activities
FAs
biosynthetic
resembling
MetS
development,
resulting
imbalance
towards
n6-series
FAs.
These
results
that
could
be
considered
new
target
for
developing
more
effective
therapeutic
approach.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(18), P. 5861 - 5861
Published: Sept. 9, 2023
Background:
Vitiligo
is
a
common
chronic
hypomelanotic
skin
disorder.
An
intricate
pool
of
markers
associated
with
complex
combination
biological
and
environmental
factors
thought
to
be
implicated
in
etiology.
This
study
aims
investigate
the
most
important
vitiligo
pathogenesis,
including
redox
status,
inflammation,
immune
profile,
patients
vitiligo.
Materials
Methods:
The
included
total
96
subjects:
30
active
non-segmental
vitiligo,
stable
36
controls.
area
severity
index
(VASI)
disease
activity
score
(VIDA)
were
determined.
following
serum
parameters
assessed:
antioxidant
status
(TAS),
superoxide
dismutase
(SOD),
catalase
(CAT),
glutathione
peroxidase
(GPx),
glutathione-S-transferase
(GST),
malondialdehyde
(MDA),
advanced
oxidation
protein
products
(AOPP),
C
reactive
(CRP),
interleukin-15
(IL-15),
chemokines
(CXCL9,
CXCL10).
Results:
VASI
was
not
significantly
different
between
patients,
as
it
approximately
0.1.
TAS,
CAT,
GPx,
GST
lower
compared
controls
(p
<
0.05).
They
also
when
However,
SOD
levels
higher
than
group
MDA
AOPP
they
did
differ
In
both
CRP
IL-15
Whereas
(range
=
2.0–7.2,
mean
4.46
±
1.09)
1.6–6.7,
3.75
1.08)
There
no
significant
difference
CXCL9
CXCL10
0.05),
Conclusions:
oxidative
damage
induces
an
increase
pro-inflammatory
IL-15,
which
turn
promotes
IFN-γ-inducible
such
CXCL10.
Further,
there
seems
link
levels.
These
data
imply
that
inhibiting
could
promising
method
for
developing
potentially
targeted
treatment
suppresses
early
interplay
oxidant
stress
keratinocyte
production,
well
resident
recirculating
memory
T
cells.
Expert Opinion on Therapeutic Targets,
Journal Year:
2023,
Volume and Issue:
27(3), P. 189 - 206
Published: March 4, 2023
Introduction
The
treatment
of
vitiligo
remains
challenging
due
to
the
complexity
its
pathogenesis,
influenced
by
genetic
factors,
oxidative
stress
and
abnormal
cell
adhesion
that
collectively
impact
melanocyte
survival
trigger
immune
system
attacks,
resulting
in
death.
Melanocytes
are
believed
exhibit
susceptibility
defects
cellular
mechanisms,
such
as
autophagy,
reduce
their
ability
resist
stress,
leading
increased
expression
pro-inflammatory
protein
HSP70.
low
molecules,
DDR1
E-cadherin,
accelerates
damage
antigen
exposure.
Consequently,
autoimmune
attacks
centered
on
IFN-γ-CXCR9/10-CXCR3-CD8+
T
cells
initiated,
causing
vitiligo.
Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Sept. 11, 2023
This
review
explores
the
psychosocial
impact
of
vitiligo
on
patients,
its
consequences
for
their
quality
life,
and
need
holistic
support.
Vitiligo's
burden,
driven
by
to
conceal
lesions
societal
beauty
ideals,
leads
stress,
sadness,
low
self-esteem.
Social
stigma
affects
self-esteem,
especially
in
cultural
contexts,
exacerbating
culturally
sensitive
Anxiety
depression
are
common
due
visible
differences
pressures.
Vitiligo
significantly
reduces
younger
impacting
daily
activities,
careers,
relationships.
Disease
severity
worsens
these
effects,
particularly
areas
among
individuals
with
darker
skin
tones.
Long-term
disease
activity
may
improve
acceptance
life.
Psychological
support
counseling
crucial,
as
many
patients
don't
seek
medical
help.
Education
plays
a
key
role,
improving
understanding
reducing
anxiety.
Raising
awareness
about
can
challenge
perceptions
contribute
enhancing
patients'
well-being.
In
conclusion,
this
highlights
interplay
between
factors,
importance
addressing
social
stigma,
providing
psychological
support,
advancing
education
those
vitiligo.
Dermatologic Therapy,
Journal Year:
2025,
Volume and Issue:
2025(1)
Published: Jan. 1, 2025
Vitiligo
is
a
complex
skin
disease
with
multiple
genes
and
targets.
Its
etiology
complex,
the
final
link
death
or
dysfunction
of
melanocytes.
Melanocytes
are
derived
from
neural
crest
cells,
their
mechanism
complex.
Currently,
more
studies
have
focused
on
apoptosis,
necrosis,
ferroptosis,
autophagy.
Aiming
to
reveal
key
terminal
stage
vitiligo:
form
melanocytes,
we
summarize
origin,
differentiation,
migration
analyze
ontogenetic
morphological
characteristics
melanocytes
various
forms
discuss
corresponding
in
this
reviews.
IntechOpen eBooks,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 6, 2025
Vitiligo’s
etiology
is
still
unclear
and
remains
the
subject
of
many
studies.
It
considered
to
be
an
autoimmune-related
disease
in
which
autoantigens
recognized
by
T
cells
from
vitiligo
patient
were
identified
during
last
decades.
Autoimmune
reactions
against
melanocytes
transfer
specific
antigens
are
required
for
development
disease.
In
addition,
environmental
factors
may
involved
vitiligo’s
triggering
or
facilitating
appearance
lesions.
Recently,
oxidative
stress
has
been
as
a
modification
microenvironment,
several
can
promote
inhibit
terms
treatments,
since
number
conventional
treatment
techniques
have
established,
therapy
advanced
significantly
few
years.
Nevertheless,
there
currently
no
permanent
vitiligo.
necessitates
determining
signaling
pathways
target
molecules
particularly
compromised
This
chapter
intends
address
pathophysiology
vitiligo,
attempts
new
developments
treatment,
biologics
Janus
kinases
(JAK)
inhibitors.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 432 - 432
Published: Jan. 11, 2025
Background:
Vitiligo
is
a
pigmentation
disorder
that
impacts
approximately
0.5%
to
2%
of
the
global
population.
Growing
interest
surrounds
comorbidities
associated
with
vitiligo.
This
study
aimed
describe
socio-demographic
characteristics
patients
vitiligo
in
Aragón
(Spain)
and
investigate
their
comorbidities.
Methods:
A
retrospective
observational
was
conducted
using
clinical
data
from
individuals
EpiChron
Cohort
(reference
population
1.3
million)
who
were
diagnosed
between
1
January
31
December
2019.
The
prevalence
chronic
calculated
logistic
regression
models,
obtaining
odds
ratio
(OR)
each
comorbidity
(dependent
variable)
according
presence
or
absence
(independent
variable).
We
used
cut-off
point
for
statistical
significance
p-value
<
0.05.
Results:
In
total,
218
analyzed.
mean
age
44.0
years,
56.42%
female.
largest
proportion
(34.86%)
aged
18
44
years.
Among
all
included,
71.5%
presented
multimorbidity,
an
average
3.21
conditions
most
frequently
included
thyroid
disorders
(OR:
3.01,
p
0.001),
ocular
hearing
abnormalities
1.54,
0.020),
inflammatory
skin
2.21,
connective
tissue
diseases
1.84,
0.007),
lower
respiratory
tract
1.78,
0.014),
urinary
infections
1.69,
0.032),
cardiac
arrhythmias
(OR
0.034).
Conclusions:
research
highlights
importance
understanding
broader
health
implications
provides
foundation
further
exploration
into
complex
interplay
this
dermatologic
condition
diverse
range
World Journal of Clinical Cases,
Journal Year:
2025,
Volume and Issue:
13(14)
Published: Jan. 14, 2025
This
article
discusses
a
case
involving
63-year-old
man
with
non-small
cell
lung
cancer,
who
was
treated
combination
of
chemotherapy
and
immunotherapy.
The
patient
five
cycles
(pemetrexed
carboplatin)
combined
sintilimab,
programmed
death
1
inhibitor.
After
the
fifth
cycle
treatment,
developed
skin
itching
vitiligo-like
rash,
which
are
known
side
effects
Despite
dermatological
consultation
treatment
topical
corticosteroids,
rash
worsened
while
subsided.
continued
after
15
cycles,
tumor
showed
response
reduction
in
size.
increased,
but
antitumor
remained
effective.
highlights
use
immunotherapy
patients
cancer
potential
effect
rash.
patient's
responded
well
to
despite
reaction,
not
discontinued
due
its
effectiveness.
suggests
that
further
studies
needed
understand
mechanism
behind
vitiligo
receiving
immune
checkpoint
inhibitors
whether
development
inhibitor
therapy
is
associated
improved
prognosis.
also
underscores
importance
managing
immune-related
adverse
events
context
effective
treatment.
Journal of Cutaneous Medicine and Surgery,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 26, 2025
Vitiligo
is
an
acquired
depigmentation
skin
disease
caused
by
the
immune-mediated
death
of
melanocytes.
It
most
common
cause
with
estimated
worldwide
prevalence
1%
but
has
shown
insufficient
response
to
current
therapies.
The
latest
research
in
vitiligo
pathogenesis
translated
into
finding
new
molecular
targets
[type
I
interferon
and
Janus
kinase
signal
transducers
transcription
activators
(JAK
STAT)
pathways],
therapies
generating
promising
results,
such
as
JAK
inhibitors.
Other
therapeutic
strategies
include
phototherapy,
surgical
treatment,
complementary
options
micropigmentation,
microneedling,
lasers.
This
review
aimed
discuss
mechanisms
involved
development
that
have
become
available,
well
evidence
on
For
this
purpose,
a
was
conducted
using
PubMed
database.
Based
review,
it
concluded
progress
understanding
pathophysiology
allowed
for
consideration
targets,
inhibitors
showing
particular
promise
both
systemic
topical
applications.
Nonetheless,
further
investigation
required
assess
safety
determine
optimal
regimen
dosage
administering
these
drugs.
Complementary
treatments
should
be
considered
case-by-case
basis.
